Understanding SL limitations

What a limitation is in law

The legal basis is Art. 73 of the Health Insurance Ordinance. The FOPH may attach a limitation to an admission to the Specialities List, relating in particular to quantity or to medical indications. In practice the office also caps treatment duration, restricts the prescriber group, or makes reimbursement conditional on cost approval.

A limitation is not a recommendation but part of the admission ruling. It operates between the insured person and the insurer: only use that complies with the limitation triggers the duty to reimburse. Swissmedic authorisation is untouched, because it governs marketability alone.

Economically, the limitation is the tool that lets the FOPH admit an expensive medicine at a bearable price: reimbursement is narrowed to the patient group in which benefit is documented, instead of rejecting the request outright.

The five practical types of limitation

Five basic patterns appear in the list, often combined in one text: indication limitation, patient or prior therapy limitation, quantity and duration limitation, cost approval, and prescriber plus price model limitation. Recognising the type tells you at once what the practice must document and what the pharmacy must check.

The price model case is the newest: the FOPH may admit a product with a confidential rebate model. Nothing changes in the practice workflow, but the whole contractual position changes for the authorisation holder.

How to read the FOPH wording correctly

Limitation texts are terse and technical. Read them in four steps: first the indication number, then the medical preconditions, then the quantity or duration figure, and last the sentence on cost approval by the health insurer. Watch the validity dates too, because many limitations are time limited.

• Indication number: several numbered indications in one text are alternative, not cumulative, preconditions.
• The sentence about assurance of cost coverage by the health insurer after prior consultation of the medical adviser makes cost approval a condition.
• Valid from and valid until: a time limited limitation lapses on the cut-off date, is extended, or is replaced by a new text.
• Limitations set at IT group level apply to every preparation in that group, even where the individual entry carries no text of its own.

That last point is the one most often missed. Always check both levels: the text on the preparation and the text published for the whole IT group. Where the two conflict, follow the narrower text.

The cost approval workflow step by step

Where the limitation requires cost approval, the insurer's assurance must exist before therapy starts. Retrospective requests are routinely refused, because the insurer can no longer assess the preconditions independently. The workflow is standardised; the timelines are not.

1. The prescriber files the request with the insurer, giving diagnosis, prior therapies, dosing, planned duration and the required findings.
2. The medical adviser reviews the file and passes on to the insurer only what the benefit assessment needs.
3. The insurer decides and confirms approval in writing, normally with an amount, a quantity and an expiry date.
4. The practice or pharmacy files the approval with the billing record and charges within the limits granted.
5. Before expiry, renewal is requested with follow-up data, because a lapsed approval covers no further dispensing.

Plan realistically for several working days. In urgent cases the urgency must be reasoned in the request; the law provides no formal emergency deadline.

When the limitation is not met

Then mandatory health insurance owes nothing, even though the product is listed and authorised for the indication. The cost falls on the insured person, on supplementary insurance, or depending on the situation on the manufacturer under a programme of its own.

Where treatment remains medically indispensable, the route is Art. 71a of the Health Insurance Ordinance. It permits reimbursement of a listed medicine outside its limitation or outside the professional information where a major therapeutic benefit is expected against a disease that may be fatal or cause severe harm, and no effective authorised alternative is available.

• Art. 71a: listed medicine used outside the limitation or the professional information.
• Art. 71b: medicine authorised in Switzerland but not listed.
• Art. 71c: medicine not authorised in Switzerland and imported.
• Always required: prior insurer cost approval after consulting the medical adviser.

How a limitation is widened and what goes wrong

The authorisation holder files a request to amend the limitation with the FOPH, supported by new clinical data and usually by a matching Swissmedic indication extension. The Federal Drug Commission assesses efficacy, appropriateness and cost effectiveness of the wider use; the FOPH then rules and adjusts the price where needed.

A widening enlarges the reimbursed patient group and therefore often pushes the price down, because the foreign price comparison and the therapeutic cross comparison are recalculated. That is why some requests are deliberately drafted narrowly.

The most common mistakes in practice

• Reading only the preparation text and missing the limitation at IT group level.
• Starting therapy and requesting cost approval afterwards.
• Forgetting to renew a time limited approval, leaving follow-up packs unreimbursed.
• Not documenting prior therapies although the limitation requires failure or intolerance.
• Treating Swissmedic authorisation as equivalent to reimbursability.
• Working from an old printout instead of checking the current monthly edition.